Home > Investors > ASX Announcements Archive (QRX)

ASX Announcements Archive (QRX)

23-May-2018	Removal from Official List

20-Apr-2018	Appendix 4C - Quarter Ended 31 March 2018

27-Mar-2018	Initial Director's Interest Notice

23-Mar-2018	Director Appointment

26-Feb-2018	Half Yearly Report and Accounts - 31 December 2017

18-Jan-2018	Appendix 4C - Quarter Ended 31 December 2017

20-Nov-2017	Results of Meeting

20-Nov-2017	Chairman's Address to Shareholders

18-Oct-2017	Notice of Annual General Meeting/Proxy Form

17-Oct-2017	Appendix 4C - Quarter Ended 30 September 2017

28-Sep-2017	Appendix 4G - Corporate Governance

28-Sep-2017	Annual Report to shareholders

30-Aug-2017	Preliminary Final Report

31-Jul-2017	Appendix 4C - Quarter Ended 30 June 2017

11-Apr-2017	Appendix 4C - Quarter Ended 31 March 2017

22-Feb-2017	Half Yearly Report and Accounts - 31 December 2016

17-Jan-2017	Appendix 4C - Quarter Ended 31 December 2016

19-Dec-2016	Auditor Appointment / Resignation

29-Nov-2016	Results of Meeting

29-Nov-2016	Chairman's Address to Shareholders

25-Oct-2016	Notice of Annual General Meeting/Proxy Form

19-Oct-2016	Appendix 4C - Quarter Ended 30 September 2016

14-Oct-2016	Initial Director's Interest Notice- J Rainbow

14-Oct-2016	Initial Director's Interest Notice- T Heesh

14-Oct-2016	Final Director's Interest Notice- B Hancox

14-Oct-2016	Final Director's Interest Notice- R Treagus

11-Oct-2016	Change in Board Composition

22-Aug-2016	Change of Registered Office & Company Secretary

18-Aug-2016	Appendix 4G - Corporate Governance Statement

18-Aug-2016	Preliminary Final Report - 30 June 2016

5-Aug-2016	Appendix 4C - Quarter Ended 30 June 2016

27-May-2016	Response to ASX Query

26-May-2016	Change of Director's Interest Notice - Bruce Hancox

19-May-2016	Results of 2015 Annual General Meeting

19-May-2016	Chairman's Address to Shareholders

10-May-2016	Appendix 4C - Quarter Ended 31 March 2016

15-Apr-2016	Notice of 2015 Annual General Meeting/Proxy Form

11-Mar-2016	Half Yearly Report and Accounts - 31 December 2015

9-Feb-2016	Appendix 4C - Quarter Ended 31 December 2015

9-Feb-2016	Appendix 4C - Quarter Ended 30 September 2015

9-Feb-2016	Appendix 4G - Corporate Governance Statement

9-Feb-2016	Annual report and full year financial results - 30 June 2015

9-Feb-2016	Appendix 4C - Quarter Ended 30 June 2015

24-Dec-2015	Letter to Shareholders

9-Dec-2015	Letter to Shareholders

7-Dec-2015	Letter to Shareholders

11-Nov-2015	Letter to Shareholders /Notice of meeting of Creditors

26-Oct-2015	Letter to Shareholders

2-Oct-2015	Letter to Shareholders

15-Sep-2015	ASX Announcement

7-Sep-2015	Letter to Shareholders

24-Jun-2015	Letter to Shareholders

22-Jun-2015	ASX Announcement

27-May-2015	Response to ASX Price Query

22-May-2015	Appointment of Voluntary Administrator

22-May-2015	Suspension from Official Quotation

22-Apr-2015	Appendix 4C - Quarter Ended 31 March 2015

2-Apr-2015	Response to ASX Price Query

10-Mar-2015	Change in substantial holding

25-Feb-2015	Half Yearly Report and Accounts - 31 December 2014

27-Jan-2015	Appendix 4C - Quarter Ended 31 December 2014

29-Oct-2014	Results of 2014 Annual General Meeting

29-Oct-2014	Chairman's Address to Shareholders

24-Oct-2014	Appendix 4C - Quarter Ended 30 September 2014

26-Sep-2014	Annual Report to Shareholders - 2014

26-Sep-2014	Notice of 2014 Annual General Meeting and Proxy Form

28-Aug-2014	2014 Annual General Meeting - Wednesday, 29 October 2014

27-Aug-2014	Preliminary Final Report - 30 June 2014

14-Aug-2014	QRxPharma Halts Moxduo Development

31-Jul-2014	QRxPharma General Shareholder Update

17-Jul-2014	Appendix 4C - Quarter Ended 30 June 2014

14-Jul-2014	Initial Director's Interest Notice - Richard Treagus

14-Jul-2014	Initial Director's Interest Notice - Bruce Hancox

14-Jul-2014	Final Director's Interest Notice - Peter Campbell

14-Jul-2014	Final Director's Interest Notice - Michael Quinn

14-Jul-2014	Final Director's Interest Notice - Gary Pace

14-Jul-2014	Final Director's Interest Notice - Peter Farrell

11-Jul-2014	Feedback on End-of-Review Meeting with the FDA on Moxduo

9-Jul-2014	Results of 9 July 2014 General Meeting

9-Jul-2014	Board Resignations and General Meeting Chairman's Address

27-Jun-2014	Letter to Shareholders from Chairman of General Meeting

26-Jun-2014	Change of Director's Interest Notice - Michael Quinn

4-Jun-2014	FDA Confirms Review Meeting Regarding MOXDUO NDA

3-Jun-2014	Notice of General Meeting/Proxy Form - 9 July 2014

29-May-2014	Change of Director's Interest Notice - Peter Campbell

29-May-2014	Change of Director's Interest Notice - Michael Quinn

29-May-2014	Change of Director's Interest Notice - Peter Farrell

26-May-2014	Complete Response Letter from FDA regarding Moxduo NDA

19-May-2014	Moxduo Status Overview May 2014

14-May-2014	Notice under Sections 249D & 203D of the Corporations Act

7-May-2014	Final Director's Interest Notice - John Holaday

7-May-2014	Change of Director's Interest Notice - Gary Pace

7-May-2014	Change of Director's Interest Notice - John Holaday

2-May-2014	Appendix 3B - Option Issue

2-May-2014	CEO Remuneration Package and Key Terms

2-May-2014	Reissue - Dr. Edward Rudnic Appointed CEO of QRxPharma

2-May-2014	Dr. Edward Rudnic Appointed CEO of QRxPharma

29-Apr-2014	Appendix 4C - Quarter Ended 31 March 2014

23-Apr-2014	CEO Discusses Moxduo Advisory Committee Meeting Outcomee

23-Apr-2014	QRxPharma Issues Statement On Moxduo Advisory Committee

22-Apr-2014	FDA Webcast Details For Moxduo Advisory Committee Meeting

17-Apr-2014	Moxduo Post Advisory Committee Meeting Investor Call Details

17-Apr-2014	Trading Halt

24-Mar-2014	FDA sets 22 April 2014 for Moxduo Advisory Committee Meeting

10-Mar-2014	Appendix 3B - Exercise of Stock Options

25-Feb-2014	ASX / Media Release - Results Half Year 31 December 2013

25-Feb-2014	Half Yearly Report and Accounts - 31 December 2013

30-Jan-2014	Appendix 3B - Exercise of Stock Options

29-Jan-2014	Appendix 4C - Quarter Ended 31 December 2013

22-Jan-2014	Details of Company Address

17-Dec-2013	Holaday - Cease to be substantial holder

17-Dec-2013	Change of Director's Interest Notice - Peter Campbell

16-Dec-2013	QRxPharma Despatches SPP Holding Statements

13-Dec-2013	Appendix 3B - Share Purchase Plan

13-Dec-2013	$4.1 Million SPP Completes A$11.6 Million Capital Raising

11-Dec-2013	25 May 2014 as New PDUFA Date for MOXDUO NDA

27-Nov-2013	MOXDUO License with TEVA for Commercialisation in Israel

26-Nov-2013	QRxPharma Refiles MOXDUO New Drug Application with the FDA

19-Nov-2013	Change in substantial holding

19-Nov-2013	Appendix 3B - Option Issue

18-Nov-2013	Notification Section 708A(5)(e) Corporations Act 2001 (Cth)

18-Nov-2013	Appendix 3B - Placement Issue announced 13 November 2013

15-Nov-2013	Share Purchase Plan Opens 19 November 2013

13-Nov-2013	Placement and SPP - ASX Listing Rule 3.10.3 Notice

13-Nov-2013	Results of 2013 Annual General Meeting

13-Nov-2013	Chairman and Managing Director Addresses to Shareholders

13-Nov-2013	Successful Completion of A$7.5 Million Placement

11-Nov-2013	Investor Update and Capital Raising - November 2013

11-Nov-2013	Trading Halt

28-Oct-2013	Appendix 4C - Quarter Ended 30 September 2013

15-Oct-2013	QRxPharma Extends MOXDUO License with Aspen

10-Oct-2013	Notice of 2013 Annual General Meeting and Proxy Form

9-Oct-2013	QRxPharma reports Positive Meeting with the FDA on MOXDUO

25-Sep-2013	Annual Report to Shareholders - 2013

17-Sep-2013	2013 Annual General Meeting - Wednesday, 13 November 2013

11-Sep-2013	QRxPharma Announces MOXDUO License with Aspen

6-Sep-2013	FDA Schedules Review Meeting Regarding MOXDUO NDA

29-Aug-2013	ASX/ Media Release - Preliminary Final Report 30 June 2013

29-Aug-2013	Preliminary Final Report - 30 June 2013

28-Aug-2013	CEO discusses Complete Response Letter on Open Briefing

28-Aug-2013	Complete Response Letter from FDA regarding MOXDUO NDA

26-Aug-2013	Trading Halt

26-Jul-2013	Appendix 4C - Quarter Ended 30 June 2013

22-Jul-2013	QRxPharma Announces Collaboration with Aesica

9-Jul-2013	Change in substantial holding

27-Jun-2013	CEO discusses MOXDUO NDA Review Update on Open Briefing

26-Jun-2013	QRxPharma Updates MOXDUO NDA Review

26-Jun-2013	Trading Halt

14-Jun-2013	Appendix 3B - Exercise of Stock Options

12-Jun-2013	QRxPharma Granted US Patent on Hybrid Opioids

5-Jun-2013	Appendix 3B - Exercise of Stock Options

17-May-2013	FDA sets 17 July 2013 for MOXDUO Advisory Committee Meeting

9-May-2013	Appendix 3B - Exercise of Stock Options

29-Apr-2013	Appendix 4C - Quarter Ended 31 March 2013

14-Mar-2013	FDA sets 26 August 2013 as new PDUFA date for MOXDUO NDA

1-Mar-2013	Investor Presentation Update - March 2013

28-Feb-2013	QRxPharma Resubmits MOXDUO New Drug Application to the FDA

21-Feb-2013	Appendix 3B - Option Issue

18-Feb-2013	Investor Presentation Update - February 2013

18-Feb-2013	Half Yearly Report and Accounts - 31 December 2012

24-Jan-2013	Appendix 4C - Quarter Ended 31 December 2012

17-Jan-2013	CEO discusses Path Forward for Resubmission of MOXDUO NDA

16-Jan-2013	Path Forward For Resubmission of MOXDUO NDA

14-Jan-2013	Appendix 3B - Exercise of Stock Options

20-Dec-2012	Appendix 3B - Exercise of Stock Options

11-Dec-2012	Investor Presentation Update - December 2012

6-Dec-2012	Change in substantial holding

6-Dec-2012	MAP Cancellation

6-Dec-2012	Change in substantial holding

28-Nov-2012	Ceasing to be a substantial holder

22-Nov-2012	Change of Director's Interest Notice - Michael Quinn

22-Nov-2012	Change of Director's Interest Notice - Gary Pace

22-Nov-2012	Change of Director's Interest Notice - Peter Farrell

21-Nov-2012	Change of Director's Interest Notice - Michael Quinn

12-Nov-2012	Change of Director's Interest Notice - John Holaday

12-Nov-2012	Appendix 3B - Option Issue

12-Nov-2012	Change of Director's Interest Notice - Peter Campbell

12-Nov-2012	Change of Director's Interest Notice - Peter Farrell

12-Nov-2012	Change of Director's Interest Notice - Michael Quinn

12-Nov-2012	Change of Director's Interest Notice - Gary Pace

7-Nov-2012	Results of 2012 Annual General Meeting

7-Nov-2012	Chairman and Managing Director Addresses to Shareholders

26-Oct-2012	Appendix 4C - Quarter Ended 30 September 2012

10-Oct-2012	Strategic Collaboration with Paladin Labs

5-Oct-2012	Notice of 2012 Annual General Meeting and Proxy Form

24-Sep-2012	Change in substantial holding

21-Sep-2012	Annual Report to Shareholders - 2012

13-Sep-2012	2012 Annual General Meeting - Wednesday, 7 November 2012

6-Sep-2012	Investor Presentation Update - September 2012

3-Sep-2012	Independent Audit Report - 30 June 2012

30-Aug-2012	ASX/ Media Release - Preliminary Final Report 30 June 2012

30-Aug-2012	Preliminary Final Report - 30 June 2012

21-Aug-2012	CEO discusses Productive Meeting with FDA regarding MOXDUO

20-Aug-2012	Productive Meeting With FDA Regarding MOXDUO NDA

24-Jul-2012	Appendix 4C - Quarter Ended 30 June 2012

11-Jul-2012	Change in substantial holding

29-Jun-2012	Ceasing to be a substantial holder from BTT

29-Jun-2012	Ceasing to be a substantial holder from WBC

27-Jun-2012	CEO discusses Complete Response Letter from FDA

27-Jun-2012	Complete Response Letter from FDA regarding MOXDUO NDA

25-Jun-2012	Trading Halt

4-Jun-2012	Ceasing to be a substantial holder

23-May-2012	QRxPharma Granted Additional US Patent on MoxDuo

21-May-2012	Appendix 3B - Exercise of Stock Options

26-Apr-2012	US Commercialisation Partner Actavis to be acquired byWatson

17-Apr-2012	Appendix 3B - Exercise of Stock Options

17-Apr-2012	Appendix 3B - Option Issue

16-Apr-2012	Appendix 4C - Quarter Ended 31 March 2012

11-Apr-2012	Successful Completion of Phase 1 Studies for MoxDuo CR

27-Mar-2012	Appendix 3B - Exercise of Stock Options

19-Mar-2012	QRxPharma Signs License and Option Agreement with Actavis

6-Mar-2012	Investor Presentation Update - March 2012

2-Mar-2012	QRxPharma Presents at Cowen Health Care Live Audio Webcast

1-Mar-2012	Appendix 3B - Exercise of Stock Options

24-Feb-2012	Half Yearly Report and Accounts - 31 December 2011

14-Feb-2012	Dr. Edward Rudnic Joins QRxPharma as Chief Operating Officer

7-Feb-2012	Appendix 3B - Exercise of Stock Options

30-Jan-2012	Appendix 4C - Quarter Ended 31 December 2011

27-Jan-2012	Appendix 3B - Option Issue

27-Jan-2012	Appendix 3B - Exercise of Stock Options

23-Jan-2012	Change in substantial holding

23-Jan-2012	Change in substantial holding

23-Jan-2012	Change in substantial holding

23-Jan-2012	Change in substantial holding

10-Jan-2012	Investor Presentation Update - January 2012

30-Dec-2011	Change of Director's Interest Notice - John Holaday

28-Dec-2011	Change in substantial holding from BTT

28-Dec-2011	Change of Interest from WBC

22-Dec-2011	Appendix 3B - Exercise of Stock Options

21-Dec-2011	QRxPharma CEO discusses Strategic Partnership with Actavis

21-Dec-2011	QRxPharma Announces Strategic Partnership with Actavis

20-Dec-2011	Trading Halt Request

20-Dec-2011	Trading Halt

29-Nov-2011	Change in substantial holding x 4

22-Nov-2011	Change of Director's Interest Notice - John Holaday

18-Nov-2011	Appendix 3B - Option Issue

16-Nov-2011	Results of 2011 Annual General Meeting

16-Nov-2011	Chairman's and Managing Director's Addresses to Shareholders

8-Nov-2011	PDUFA Target Date for FDA Action on MoxDuo IR NDA Granted

4-Nov-2011	Appendix 3B - Exercise of Stock Options

27-Oct-2011	Appendix 4C - Quarter Ended 30 September 2011

17-Oct-2011	Appendix 3B - Option Issue

14-Oct-2011	2011 Notice of Annual General Meeting and Proxy Form

28-Sep-2011	Appendix 3B - Exercise of Stock Options

27-Sep-2011	Annual Report to Shareholders - 2011

20-Sep-2011	Change in substantial holding

7-Sep-2011	Becoming a substantial holder

1-Sep-2011	Change of Director's Interest Notice - Peter Farrell

1-Sep-2011	Change of Director's Interest Notice - Gary Pace

1-Sep-2011	Change of Director's Interest Notice - Michael Quinn

1-Sep-2011	Change of Director's Interest Notice - Peter Campbell

30-Aug-2011	Appendix 3B - Rights Issue

30-Aug-2011	Non-renounceable Rights Issue Despatch of Holding Statements

25-Aug-2011	QRxPharma Completes NDA Submission for MoxDuo IR

25-Aug-2011	Non-renounceable Rights Issue Notice of under subscriptions

18-Aug-2011	ASX/ Media Release - Preliminary Final Report 30 June 2011

18-Aug-2011	Preliminary Final Report - 30 June 2011

15-Aug-2011	Corporate Update and Rights Issue closing 22 August 2011

12-Aug-2011	Change of Director's Interest Notice - Michael Quinn

10-Aug-2011	Correction Web Address - CEO discussion on Boardroom Radio

10-Aug-2011	CEO on Recent Milestones and Rights Issue - Boardroom Radio

8-Aug-2011	Notice of Despatch of Rights Issue Documents to Shareholders

8-Aug-2011	Rights Issue - Notice to Ineligible Shareholders

8-Aug-2011	Rights Issue - Letter to U.S. Eligible Shareholders

2-Aug-2011	Appendix 3B - Exercise of Stock Options

28-Jul-2011	Appendix 4C - Quarter Ended 30 June 2011

27-Jul-2011	Notification Section 708A(5)(e) Corporations Act

22-Jul-2011	QRxPharma Rights Issue - Entitlement and Acceptance Form

22-Jul-2011	Non-Renounceable Rights Issue - Letter to Shareholders

22-Jul-2011	Non-Renounceable Rights Issue - Letter to Option Holders

22-Jul-2011	QRxPharma Rights Issue Booklet

22-Jul-2011	Notification Section 708AA(2)(f) Corporations Act

22-Jul-2011	Appendix 3B - Placement and Rights Issue

22-Jul-2011	QRxPharma Announces A$35 Million Capital Raising

20-Jul-2011	Investor Update and Capital Raising - 20 July 2011

20-Jul-2011	Trading Halt

18-Jul-2011	QRxPharma Announces NDA Filing for MoxDuo IR

13-Jul-2011	Appendix 3B - Option Issue

29-Jun-2011	Additional Data on MoxDuo IR Comparative Safety Study

20-Jun-2011	Investor Presentation Update - June 2011

15-Jun-2011	CEO discusses Comparative Safety Study on Boardroom Radio

14-Jun-2011	Successful Completion MoxDuo IR Comparative Safety Study

17-May-2011	Presentation of Clinical Data on MoxDuoTrials at APS Meeting

13-May-2011	Appendix 3B - Exercise of Stock Options

28-Apr-2011	Appendix 4C - Quarterly Report 31 March 2011

27-Apr-2011	Enrolment of MoxDuo IR Comparative Safety Study Completed

14-Apr-2011	USPTO Issues QRxPharma a New Patent for MoxDuo IR

8-Apr-2011	Change in substantial holding

7-Apr-2011	Change in substantial holding

28-Mar-2011	QRxPharma on Track to File New Drug Application Mid-Year

16-Mar-2011	Ceasing to be a substantial holder

21-Feb-2011	Half Yearly Report and Accounts -31 December 2010

21-Feb-2011	Investor Presentation Update - February 2011

21-Feb-2011	Successful Completion Third Pivotal MoxDuo IR Phase 3

27-Jan-2011	Appendix 4C - 31 December 2010

24-Jan-2011	Initiation of Phase 3 Comparative Safety Study of MoxDuo IR

6-Jan-2011	Appendix 3B - Option Issue

31-Dec-2010	QRxPharma Securities Trading Policy

6-Dec-2010	Enrolment of Pivotal MoxDuo IR Phase 3 Study Completed

26-Nov-2010	Change of Director's Interest Notice - Peter Campbell

26-Nov-2010	Change of Director's Interest Notice - Michael Quinn

19-Nov-2010	Appendix 3B - Share Purchase Plan

19-Nov-2010	$5.8 million SPP completes capital raising of $19.8 million

15-Nov-2010	Change of Director's Interest Notice - Michael Quinn

15-Nov-2010	Change of Director's Interest Notice - Gary Pace

15-Nov-2010	Change of Director's Interest Notice - Peter Campbell

15-Nov-2010	Change of Director's Interest Notice - John Holaday

15-Nov-2010	Change of Director's Interest Notice - Peter Farrell

12-Nov-2010	Change in substantial holding

9-Nov-2010	Appendix 3B - Option Issue

9-Nov-2010	Notification Section 708A(5)(e) Corporations Act 2001 (Cth)

9-Nov-2010	Appendix 3B - 2nd Tranche of Placement Issue

8-Nov-2010	Amended Company Constitution 8 November 2010

8-Nov-2010	Results of 2010 Annual General Meeting

8-Nov-2010	Chairman's and Managing Directors' Addresses to Shareholders

8-Nov-2010	Additional U.S.Therapeutic Discovery Project Grant Awarded

4-Nov-2010	Appendix 3B - Exercise of Stock Options

4-Nov-2010	MoxDuo Awarded U.S. Therapeutic Discovery Project Grants

27-Oct-2010	Appendix 3B - Option Issue

27-Oct-2010	Appendix 4C -30 September 2010

15-Oct-2010	Becoming a substantial holder

15-Oct-2010	Share Purchase Plan_Opens 18 October 2010

8-Oct-2010	2010 Annual Report to Shareholders - Printed and Web Copy

8-Oct-2010	Notice of Annual General Meeting/Proxy Form

7-Oct-2010	Notification Section 708A(5)(e) Corporations Act 2001 (Cth)

7-Oct-2010	Appendix 3B - Placement Issue announced 1 October 2010

6-Oct-2010	Appendix 3B - Option Issue

1-Oct-2010	Placement and Share Purchase Plan Listing Rule 3.10.3 Notice

1-Oct-2010	A$14 Million Placement together with a Share Purchase Plan

29-Sep-2010	Investor Update and Capital Raising - 29 September 2010

29-Sep-2010	Annual Report to shareholders - 2010

29-Sep-2010	Trading Halt

21-Sep-2010	Appendix 3B - Option Issue

1-Sep-2010	Interim Analysis of Final Pivotal Phase 3 Study MoxDuoIR

26-Aug-2010	ASX/ Media Release - Preliminary Final Report 30 June 2010

26-Aug-2010	Preliminary Final Report - 30 June 2010

18-Aug-2010	MoxDuo IR recognised for innovation in pain therapy

9-Aug-2010	Positive Phase 2 Proof of Concept Data for MoxDuoIV

26-Jul-2010	Investor Presentation Update July 2010

26-Jul-2010	Positive Scientific Advice Meetings in Europe MoxDou IR

26-Jul-2010	Appendix 4C - 30 June 2010

7-Jul-2010	Appendix 3B - Option Issue

21-Jun-2010	Appendix 3B- - Exercise of Stock Options

3-Jun-2010	Appendix 3B - Exercise of Stock Options

28-May-2010	Ceasing to be a substantial holder

10-May-2010	Phase 1 PK Study for MoxDuoCR Tablet Formula Successful

6-May-2010	Response to ASX Query - Appendix 4C

4-May-2010	Investor Presentation Update May 2010

4-May-2010	Phase 3 Combination Rule Study for MoxDuo IR Additional Data

27-Apr-2010	Appendix 4C - Quarterly Report 31 March 2010

23-Apr-2010	Appendix 3B - Exercise of Stock Options

14-Apr-2010	Phase 3 Combination Rule Study for MoxDuoIR Successful

9-Apr-2010	Becoming a substantial holder

9-Apr-2010	Ceasing to be a substantial holder

1-Apr-2010	Appendix 3B - Exercise of Stock Options

1-Apr-2010	Appendix 3B - Option Issue

30-Mar-2010	Phase 1 Trial of Controlled-Release Dual-Opioid Initiated

18-Mar-2010	Appendix 3B - Exercise of Stock Options

10-Mar-2010	Change in substantial holding

25-Feb-2010	Appendix 3B - Exercise of Stock Options

23-Feb-2010	Strategic Alliance for Development of MoxDuo IV

22-Feb-2010	Appendix 3B - Option Issue

17-Feb-2010	Half Yearly Report and Accounts - 31 December 2009

10-Feb-2010	QRxPharma Initiates Second Pivotal Phase 3 Study MoxDuoIR

27-Jan-2010	Appendix 4C - Quarterly Report 31 December 2009

18-Jan-2010	Change in substantial holding - John Holaday

18-Jan-2010	Becoming a substantial holder - John Holaday

11-Jan-2010	Appendix 3B - Option Issue

6-Jan-2010	Becoming a substantial holder

30-Dec-2009	Change in substantial holding from BTT

30-Dec-2009	Change in substantial holding from WBC

23-Dec-2009	Change of Director's Interest Notice - Gary Pace

23-Dec-2009	Change of Director's Interest Notice - John Holaday

23-Dec-2009	Change of Director's Interest Notice - Michael Quinn

23-Dec-2009	Change of Director's Interest Notice - Peter Farrell

23-Dec-2009	Change of Director's Interest Notice - Peter Campbell

23-Dec-2009	Appendix 3B - Rights Issue

23-Dec-2009	Change in substantial holding

21-Dec-2009	Rights Issue - Notice of Despatch of Shareholder Statements

18-Dec-2009	Appendix 3B - Rights Issue

18-Dec-2009	Notice of Subscriptions under Rights Issue

18-Dec-2009	Change of Director's Interest Notice - Michael Quinn

11-Dec-2009	Change of Director's Interest Notice - Michael Quinn

10-Dec-2009	Change of Director's Interest Notice - Gary Pace

10-Dec-2009	Change of Director's Interest Notice - John Holaday

10-Dec-2009	Corporate Update and Rights Issue closing 15 December 2009

30-Nov-2009	QRxPharma Initiates Pivotal Phase 3 Study of MoxDuoIR

30-Nov-2009	Notice of Despatch of Rights Issue Documents to Shareholders

30-Nov-2009	Rights Issue - Notice to Ineligible Shareholders

30-Nov-2009	Rights Issue - Letter to U.S. Eligible Shareholders

23-Nov-2009	Change of Director's Interest Notice - John Holaday

23-Nov-2009	Appendix 3B - Option Issue

20-Nov-2009	Becoming a substantial holder

19-Nov-2009	Appendix 3B - Placement Issue announced on 16 November 2009

16-Nov-2009	Results of 2009 Annual General Meeting

16-Nov-2009	Chairman's and Managing Directors' Addresses to Shareholders

16-Nov-2009	Reinstatement to Official Quotation

16-Nov-2009	Renounceable Rights Issue - Letter to Shareholders

16-Nov-2009	Renounceable Rights Issue - Letter to Option holders

16-Nov-2009	Appendix 3B - Placement and Rights Issue

16-Nov-2009	Notification Section 708AA(2)(f) Corporations Act 2001 (Cth)

16-Nov-2009	Renounceable Rights Issue - Entitlement and Acceptance Form

16-Nov-2009	QRxPharma Renounceable Rights Issue Booklet

16-Nov-2009	A$21.6 Million Fully Underwritten Placement and Rights Issue

13-Nov-2009	Investor Update and Capital Raising 13 November 2009

13-Nov-2009	Suspension from Official Quotation

11-Nov-2009	QRxPharma Investor Update and Capital Raising

11-Nov-2009	Trading Halt

26-Oct-2009	Appendix 4C - Quarterly Report 30 September 2009

20-Oct-2009	Completion of Strategic Alliance Deal for Venomics Assets

12-Oct-2009	Deal inked with Patheon for the Manufacture of MoxDou CR

12-Oct-2009	Notice of Annual General Meeting/Proxy Form

6-Oct-2009	Appendix 3B - Option Issue

29-Sep-2009	Ceasing to be a substantial holder

28-Sep-2009	Annual Report to Shareholders - 2009

28-Sep-2009	Change in substantial holding

25-Sep-2009	Change in substantial holding

24-Sep-2009	Strategic Alliance for the Development of Venomics Assets

31-Aug-2009	Appendix 3B - Option Issues

26-Aug-2009	Corporate Presentation Update August 2009

25-Aug-2009	MoxDuoIR Demonstrates Fewer Side Effects than Percocet

21-Aug-2009	ASX/ Media Release - Preliminary Final Report 30 June 2009

21-Aug-2009	Preliminary Final Report - 30 June 2009

29-Jul-2009	Response to ASX Query - Change of Director's Interest

28-Jul-2009	Appendix 4C - Quarterly Report 30 June 2009

23-Jul-2009	QRxPharma Initiates Comparative Phase 2 Sudy for MoxDuo IV

20-Jul-2009	Change of Director's Interest Notice - Michael Quinn

25-May-2009	Appendix 3B - Release of Shares from ASX Restriction

11-May-2009	Release of Shares from Voluntary Escrow and ASX Restriction

29-Apr-2009	Corporate Presentation Update April 2009

27-Apr-2009	Appendix 4C - Quarterly Report 31 March 2009

20-Apr-2009	Successful Completion of Comparative Study for MoxDuoIR

9-Mar-2009	Appendix 3B - Option Issues

9-Mar-2009	Change of Director's Interest Notice - Peter Farrell

23-Feb-2009	Half Yearly Report and Accounts 31 December 2008

19-Feb-2009	QRxPharma Initiates Second Comparative Study for MoxDuo IR

29-Jan-2009	Change in substantial holding

28-Jan-2009	Appendix 4C - Quarterly Report December 2008

22-Jan-2009	Dr Jesus Soriano as Executive Vice President

16-Dec-2008	QRxPharma Initiates Comparative Study for MoxDuoIR

10-Dec-2008	Change in substantial holding

9-Dec-2008	Becoming a substantial holder

4-Nov-2008	Chairman's and CEO's Address to Shareholders

4-Nov-2008	Results of 2008 Annual General Meeting

24-Oct-2008	Appendix 4C - Quarter Ended 30 September 2008

26-Sep-2008	Annual Report to Shareholders - 2008

26-Sep-2008	Notice of Annual General Meeting/Proxy Form

21-Aug-2008	ASX/ Media Release - Preliminary Final Report 30 June 2008

21-Aug-2008	Preliminary Final Report - 30 June 2008

12-Aug-2008	Change of Director's Interest Notice - Peter Farrell

5-Aug-2008	FDA Accepts Streamlined Phase 3 Development Plan Q8003IR

30-Jul-2008	Appendix 4C - 30 June 2008

3-Jul-2008	Change of Director's Interest Notice - Michael Quinn

1-Jul-2008	QRxPharma Begins Trading on the International OTCQX

1-Jul-2008	Change of Director's Interest Notice - Peter Campbell

30-Jun-2008	Change of Director's Interest Notice - John Holaday

27-Jun-2008	Change of Director's Interest Notice - Peter Farrell

3-Jun-2008	QRxPharma Corporate Presentation - June 2008

3-Jun-2008	QRxPharma Launches ADR Program

22-May-2008	Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy

19-May-2008	Appendix 3B - Release of Shares from Restriction and Escrow

5-May-2008	Initial Phase 3 Study Results Dual Opioid Pain Therapy

5-May-2008	Corporate Presentation Update May 2008

28-Apr-2008	Appendix 4C - quarterly

1-Apr-2008	Appendix 3B - Option Issues

26-Feb-2008	Half Yearly Report and Accounts

15-Feb-2008	Company Secretary Appointment/Resignation

29-Jan-2008	Appendix 4C - Quarterly 31 December 2007

7-Jan-2008	QRxPharma Reports Feedback from the FDA - Q8003IR

4-Jan-2008	Change of Director's Interest Notice - Gary Pace

28-Dec-2007	Change of Director's Interest Notice - Gary Pace

20-Dec-2007	Ceasing to be a substantial holder

13-Dec-2007	QRxPharma Initiates Second Phase III Clinical Trial

6-Dec-2007	Change of Director's Interest Notice - Micahel Quinn

6-Dec-2007	Change of Director's Interest Notice - Michael Quinn

30-Nov-2007	Change of Director's Interest Notice - Peter Farrell

30-Nov-2007	Details of Company Address

30-Nov-2007	Quotation of Securities

26-Nov-2007	QRxPharma Enrolls First Patients in Phase III Clinical Trial

15-Nov-2007	Change of Director's Interest Notice - John Holaday

2-Nov-2007	Results of Meeting

2-Nov-2007	Chairman's Address to Shareholders

29-Oct-2007	QRxPharma Limited - Investor Update October 2007

25-Oct-2007	Change in substantial holding from WBC

22-Oct-2007	Appendix 4C - quarterly

27-Sep-2007	Annual Report to shareholders

27-Sep-2007	Notice of Annual General Meeting/Proxy Form

15-Aug-2007	Company Presentation Preliminary Final Report

15-Aug-2007	ASX/ Media Release - Preliminary Final Report

15-Aug-2007	Preliminary Final Report

7-Aug-2007	Becoming a substantial holder from WBC

3-Aug-2007	Ceasing to be a substantial holder from WBC

2-Aug-2007	Initial Substantial Shareholder Notice from WBC

27-Jul-2007	Appendix 4C - quarterly

19-Jun-2007	Release of Shares from Escrow

14-Jun-2007	Change of Director's Interest Notice

12-Jun-2007	Becoming a substantial holder

31-May-2007	Change of Director's Interest Notice

31-May-2007	Change of Director's Interest Notice

31-May-2007	Initial Director's Interest Notice

31-May-2007	Initial Director's Interest Notice

31-May-2007	Initial Director's Interest Notice

31-May-2007	Initial Director's Interest Notice

31-May-2007	Initial Director's Interest Notice

25-May-2007	QRxPharma Limited completes IPO/Trading commences on ASX

25-May-2007	Pre-Quotation Disclosure

25-May-2007	Top 20 shareholders

25-May-2007	Distribution Schedule

25-May-2007	Admission to Official List

24-May-2007	ASX Circular: Commencement of Official Quotation

24-May-2007	Constitution

24-May-2007	Pre-quotation Disclosure re Shares and Options

24-May-2007	Financial Statements 31 December 2006

24-May-2007	Financial Statements 30 June 2006

24-May-2007	Financial Statements 30 June 2005

24-May-2007	Financial Statements 30 June 2004

23-May-2007	Corporate Governance Statement

23-May-2007	Full terms & conditions of ESOP

21-May-2007	Appendix 1A: ASX Listing application and agreement

16-May-2007	Disclosure Document